InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Oruka Therapeutics, Inc.

ORKA Clue Score22
United States Fiscal year ends December CIK 0000907654
$82.11 +6.25% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $82.11 +2,952.42% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 12 Oct 2016. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2016Revenue0.0Operating income−16.6Net income−16.4Fiscal year 2017Revenue0.0Operating income−18.7Net income−18.5Fiscal year 2018Revenue0.0Operating income−8.1Net income−7.9Fiscal year 2019Revenue0.0Operating income−5.8Net income−5.5Fiscal year 2020Revenue0.0Operating income−9.8Net income−9.7Fiscal year 2021Revenue0.0Operating income−19.3Net income−19.3EPS, diluted−1.39Fiscal year 2022Revenue0.0Operating income−10.6Net income−9.9EPS, diluted−0.69Fiscal year 2023Revenue0.0Operating income−7.3Net income−5.3EPS, diluted−0.37Fiscal year 2025Operating income−122.1Net income−105.4
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2025
Revenue 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 n/a
Growth
Operating income −16.6 −18.7 −8.1 −5.8 −9.8 −19.3 −10.6 −7.3 −122.1
Net income −16.4 −18.5 −7.9 −5.5 −9.7 −19.3 −9.9 −5.3 −105.4
Growth
EPS, diluted n/a n/a n/a n/a n/a −1.39 −0.69 −0.37 n/a
Growth

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2016Operating cash flow−15.0Capital expenditure−0.0Free cash flow−15.0Fiscal year 2017Operating cash flow−17.5Capital expenditure−0.0Free cash flow−17.5Fiscal year 2018Operating cash flow−8.2Capital expenditure−0.0Free cash flow−8.2Fiscal year 2019Operating cash flow−4.8Capital expenditure−0.0Free cash flow−4.8Fiscal year 2020Operating cash flow−7.7Capital expenditure−0.0Free cash flow−7.7Fiscal year 2021Operating cash flow−18.8Capital expenditure−0.0Free cash flow−18.8Fiscal year 2022Operating cash flow−10.9Capital expenditure−0.0Free cash flow−10.9Fiscal year 2023Operating cash flow−5.0Capital expenditure0.0Free cash flow−5.0Fiscal year 2025Operating cash flow−88.2Capital expenditure−0.2Free cash flow−88.4
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2025
Operating cash flow −15.0 −17.5 −8.2 −4.8 −7.7 −18.8 −10.9 −5.0 −88.2
Capital expenditure −0.0 −0.0 −0.0 −0.0 −0.0 −0.0 −0.0 0.0 −0.2
Free cash flow −15.0 −17.5 −8.2 −4.8 −7.7 −18.8 −10.9 −5.0 −88.4
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2016Cash7.4Shareholders’ equity22.2Fiscal year 2017Cash8.7Shareholders’ equity10.3Fiscal year 2018Cash6.6Shareholders’ equity6.0Fiscal year 2019Cash8.4Shareholders’ equity7.6Fiscal year 2020Cash49.1Shareholders’ equity46.5Fiscal year 2021Cash53.4Shareholders’ equity51.0Fiscal year 2022Cash42.4Shareholders’ equity41.7Fiscal year 2023Cash37.4Shareholders’ equity37.0Fiscal year 2025Cash46.9Shareholders’ equity471.9
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2025
Cash 7.4 8.7 6.6 8.4 49.1 53.4 42.4 37.4 46.9
Shareholders’ equity 22.2 10.3 6.0 7.6 46.5 51.0 41.7 37.0 471.9

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2016 31 Dec 2016 FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2025 31 Dec 2025
Returns
−74.1% −180.0% −131.5% −72.0% −20.9% −37.9% −23.8% −14.4% −22.3%
−66.8% −149.5% −116.2% −64.2% −19.3% −35.2% −23.0% −14.1% −21.6%
Balance and payout
9.9% 16.9% 11.6% 10.8% 7.7% 7.1% 3.3% 2.2% 3.4%